$TLX News
Last published 1d ago
- 1d agoTLXTelix to Participate in UBS Global Biopharma ConferencePR NewswireTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK)....
- 6d agoPROFTLXProfound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of GrowthGlobeNewswireGross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or
- 1w agoTLXTelix Pharmaceuticals Limited - Capital Markets Day - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsAll right. Thank you, everybody. Thank you to those in the room and online. For those who don't know me, my name is Kai Williamson, SVP of Investor Relations and Corporate Communication at Telex. It's my pleasure to welc
- 1w agoTLXTelix Pharmaceuticals Limited - Capital Markets Day - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsAll right. Thank you, everybody. Thank you to those in the room and online. For those who don't know me, my name is Kai Williamson, SVP of Investor Relations and Corporate Communication at Telex. It's my pleasure to welc
- 3w agoTLXTelix Reports Third Quarter 2026 Financial PerformanceGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") provides a financial update on its commercial and operational performance
- 3w agoTLXTelix and Ekalia to Collaborate on Astatine-211 Production in the U.S.GlobeNewswireCollaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).Secures long-term,
- 1mo agoPROFTLXProfound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate CareGlobeNewswireCollaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® Agreement provides Profound with
- 1mo agoTLXTelix and ITM Join Forces to Create a Radiopharmaceutical PowerhousePR NewswireTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has signed a strategic agreement to lead a merger with ITM Isotope...
- 1mo agoTLXTelix and ITM Join Forces to Create a Radiopharmaceutical PowerhouseGlobeNewswireTransformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing,
- 1mo agoTLXTELIX PHARMACEUTICALS LIMITED – INVESTOR CONFERENCE CALL - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsGood morning and good evening everybody and thank you so much for joining us today to discuss the announcement we made a short time ago regarding the merger of Keelix and ITM. If we could just move to the next slide plea
- 1mo agoTLXTelix Pharmaceuticals Limited – Investor Conference Call - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsGood morning and good evening everybody and thank you so much for joining us today to discuss the announcement we made a short time ago regarding the merger of Keelix and ITM. If we could just move to the next slide plea
- 1mo agoTLXTelix - 1774223 - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsOkay, good morning everyone. We might get started. My name is David Bailey. I'm part of the healthcare team at Morgan Stanley based in Australia. Joined today by Chris Berenbrook and Kevin Richardson, CEO and CEO of Prec
- 1mo agoTLXMorgan Stanley 24th Annual Global Healthcare Conference - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsOkay, good morning everyone. We might get started. My name is David Bailey. I'm part of the healthcare team at Morgan Stanley based in Australia. Joined today by Chris Berenbrook and Kevin Richardson, CEO and CEO of Prec
- 1mo agoTLXFDA Approves Telix’s Brain Cancer Imaging Drug PixclaraGlobeNewswirePixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related
- 2mo agoTLXTelix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that Dr. Christian Behrenbruch, Managing Director and Group CEO
- 2mo agoTLXTelix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA PathwayGlobeNewswireThe Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.Telix has positively engaged with the FDA on a New Drug Application
- 2mo agoTLXEOLSTelix Appoints David Gill as ChairGlobeNewswireDavid Gill appointed Chair of the Telix Board, effective immediately.Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.Dr. Mark Nelson will continue to serve on
- 2mo agoTLXTelix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage PipelineGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the period ended June 30,
- 2mo agoTLXTELIX - H1 2026 RESULTS AND INVESTOR WEBCAST - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsGood morning and good evening everybody. My name is Kyanne Williamson, SVP of Investor Relations and Corporate Communications at Telex and it's my pleasure to welcome you today to our H1 2026 interim results presentation
- 2mo agoTLXTELIX - H1 2026 RESULTS AND INVESTOR WEBCAST - TELIX PHARMACEUTICALS LTDEarnings Call TranscriptsGood morning and good evening everybody. My name is Kyanne Williamson, SVP of Investor Relations and Corporate Communications at Telex and it's my pleasure to welcome you today to our H1 2026 interim results presentation
- 3mo agoTLXTelix to Host R&D Day in New York City on September 22, 2026GlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will host a Research and Development (R&D) Day
- 3mo agoTLXTelix H1 2026 Results: Investor Webcast NotificationGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will release its financial results for the half-year
- 3mo agoTLXTLX591-Tx ProstACT SELECT Study Published in Cancers JournalGlobeNewswirePeer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with previously reported
- 3mo agoTLXTelix Q2 Revenue US$247M, Strong Momentum and Pipeline ProgressGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") provides a market update on its commercial and operational performance for
- 3mo agoTLXTelix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal CancerGlobeNewswireFirst patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in
- 3mo agoTLXFirst Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate CancerGlobeNewswireFirst patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney.OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer
- 4mo agoTLXFDA Alignment to Advance ProstACT Global Phase 3 TrialGlobeNewswireFDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination
- 4mo agoTLXTelix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic DirectionsGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces an educational webinar exploring the unmet needs in
- 5mo agoTLXTelix and United Imaging Announce Strategic Theranostics CollaborationGlobeNewswirePartnership to evaluate Telix's innovative precision medicine products and candidates in combination with United Imaging's advanced scanner platforms.Initial focus on TLX101-Px (Pixclara®1, Floretyrosine F 18) in
- 5mo agoTLXProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026GlobeNewswireTelix's first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals.Findings
- 5mo agoTLXTelix to Participate in William Blair Growth Stock and Jefferies Global Healthcare ConferencesGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will
- 5mo agoTLXIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms DosingGlobeNewswireIPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.Maximum dose reached with no dose-limiting toxicities observed.TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively
- 6mo agoEDAPPROFTLXTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesGlobeNewswireTelix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
- 6mo agoEDAPTLXEDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate CancerGlobeNewswire, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix") to explore joint
- 6mo agoTLXNew Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCCGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the publication of a new independent analysis of Phase 3 ZIRCON
- 6mo agoTLXTLX101-Px (Pixlumi®) MAA Accepted in EuropePR NewswireTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application (MAA) filed in Europe for ...
- 6mo agoTLXTLX101-Px (Pixlumi®) MAA Accepted in EuropeGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the marketing authorization application (MAA) filed in Europe
- 6mo agoTLXOPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate CancerGlobeNewswireTLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer.OPTIMAL-PSMA2 initial dosimetry data demonstrate low
- 6mo agoTLXEducational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio ApproachGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") announces an educational webinar exploring the evolution of PSMA1-targeted
- 6mo agoTLXProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026GlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that safety and tolerability data from the ProstACT Global Phase 3
- 7mo agoTLXTelix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent GlioblastomaGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the first patient has been dosed with TLX101-Tx
- 7mo agoTLXTelix Successfully Prices and Upsizes US$600 Million Convertible BondsPR NewswireTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") is pleased to announce that it has successfully priced and upsized its 1.50 per cent...
- 7mo agoTLXTelix Refinances Convertible BondsPR NewswireTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") today launches an offering of US$550 million convertible notes due 2031 to be issued...
- 7mo agoREGNTLXTelix and Regeneron Announce Strategic Radiopharma CollaborationGlobeNewswireTelix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.Collaboration combines Telix's expertise in radiopharmaceutical development
- 7mo agoREGNTLXRegeneron and Telix Announce Strategic Radiopharma CollaborationGlobeNewswireRegeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron's leading antibody discovery/development
- 7mo agoTLXFDA Accepts NDA for TLX101-Px (Pixclara®)GlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA)
- 7mo agoANIKAVNTCOOMASI+3Telix Strengthens Board with Additional Director AppointmentsGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments,
- 7mo agoTLXQ1 2026: Strong Revenue Growth and Therapeutics Pipeline AdvancementGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") provides a market update on its commercial and operational performance for the
- 7mo agoEOLSTLXTelix Appoints David Gill as Non-Executive DirectorGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED),
- 8mo agoTLXTelix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging CandidateGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the resubmission of a New Drug Application (NDA) to the United